期刊文献+

不同类型HBV感染人群T细胞对HBV抗原蛋白免疫应答的差异分析 被引量:2

The variance analysis of immune responses between different HBV antigens and different types of T cells in HBV-infected people
下载PDF
导出
摘要 目的探讨不同类型乙肝病毒(HBV)感染者免疫T细胞群(CD4T和CD8T)对乙肝病毒抗原蛋白免疫应答的特点及差异性。方法选取107例HBV感染患者为研究对象,根据患者病情分为HBV携带组(A组)32例、急性乙肝组(B组)38例、慢性乙肝组(C组)37例,同时选取既往HBV组41例作为对照组,分别对上述4组患者应用免疫荧光分析仪检测免疫T细胞对HBeAg、HBcAg、HBsAg等HBV特异性抗原蛋白的免疫应答。结果急性乙肝患者ALT、AST、总胆红素含量以及慢性乙肝组患者HBV DNA含量显著高于其他各组,差异具有统计学意义(P<0.05)。反应频率分析:急性乙肝患者对HBV常见的3种抗原蛋白阳性反应频率与慢性乙肝患者相比无统计学意义。HBV携带组对HBeAg的反应频率显著高于HBcAg及HBsAg(P<0.05)。既往HBV组对HBsAg的反应频率显著低于HBcAg及HBeAg(P<0.05)。反应强度分析:1)HBeAg反应强度:B显著高于其余各组(P<0.05),A、C相比无统计学意义,对照组高于A组(P<0.05)。2)HBcAg反应强度:对照组>B组>C组>A组,两两相比差异有统计学意义(P<0.05)。3)HBsAg反应强度:B组>C组>A组=对照组。4)A组组内对比:HBeAg反应强度高于HBsAg及HBcAg(P<0.05),HBsAg与HBcAg相比无统计学意义(P>0.05)。5)B组组内对比:HBeAg>HBsAg>HBcAg,比较有统计学意义(P<0.05)。6)C组内对比:HBcAg反应强度大于HBeAg及HBsAg(P<0.05),而HBeAg和HBsAg无统计学意义(P>0.05)。结论通过检测HBV感染者T细胞群(CD4T和CD8T)对乙肝病毒抗原蛋白免疫应答可预测患者病情的发展,可为HBV诊断提供指导性依据。 To explore the characteristics and differences of different types of hepatitis B virus (HBV) infection by observing immune reponse between T cell and HBV antigen protein, 107 cases of HBV infection patients were divided into HBV carrier group A (n=32), acute hepatitis group B (n=38), chronic hepatitis group C (n=37), with previous HBV patients (n=41) as controls. T cells and the immune response of HBeAg, HBeAg, HBsAg of 4 groups were analyzed by immune fluorescence analyzer. General situation analysis showed that ALT, AST, and total bilirubin levels in patients with acute hepatitis B and HBV DNA content in patients with chronic hepatitis B were significantly higher than those in other groups (P〈 0.05). While response frequency analysis illustrated that positive reaction frequency of three common HBV antigens has no statistical difference in patients with acute hepatitis B and chronic hepatitis B; HBV carrier group had a significantly higher response frequency of HBeAg than HBcAg and HBsAg (P〈 0.05); previous HBV group had a significantly lower response frequency of HBsAg than HBcAg and HBeAg (P 〈 0.05). Reaction intensity analysis showed that the reaction intensity of HBeAg in acute hepatitis group and HBV carrier group was the highest, the reaction intensity of HBcAg in chronic hepatitis group and control group was the highest, while the reaction intensity of HBsAg in acute hepatitis group was the highest than the rest of the group (P〈 0.05). We conclude that the detection of T cell responses to hepatitis B virus antigen protein may predict the development of the patient's condition, and thus be used as guidance for HBV diagnosis.
出处 《免疫学杂志》 CAS CSCD 北大核心 2013年第11期984-987,共4页 Immunological Journal
关键词 乙肝 HBV感染 T细胞 抗原蛋白 Hepatitis B HBV infection T cells Antigen protein
  • 相关文献

参考文献11

二级参考文献80

共引文献17138

同被引文献23

  • 1Lavanehy D. Chronic viral hepatitis as a public health issue in the world[J]. Best Praet Res Clin Gastroenterol, 2008, 22(6): 991-1008. 被引量:1
  • 2Manolakopoulos S, Bethanis S, Koutsounas S, et al. Long- term therapy with adefovir dipivoxil in hepatitis B e antigen -negative patients developing resistance to lamivudine[J]. Aliment Pharmacol Ther, 2008, 27(3): 266- 273. 被引量:1
  • 3Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B[J]. Expert Opin Investig Drugs, 2003,12(4): 683-688. 被引量:1
  • 4Schm ilovitz WH, Ben AZ, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study[J]. Liver Int, 2004, 24(6): 547- 551. 被引量:1
  • 5Park IH, Back KW, Cho EY, et al. PKR-dependent mechanisms of interferon-alpha for inhibiting hepatitis B virus replication[J]. Mol Cells, 2011, 32(2): 167-172. 被引量:1
  • 6Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades [J]. J Gastroenterol Hepatol, 2011, 26(Suppl 1): 138-143. 被引量:1
  • 7Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B eantigen-negative chronic hepatitis[J]. Gastroenterology, 2001, 121(1): 101-1091. 被引量:1
  • 8Im SJ, Yang SH, Yoon SK, et al. Increase of plasma IL-12/ p40 ratio induced by the combined therapy of DNA vaccine and lamivudine correlates with sustained viremia control in CHB carriers[J]. Immune Netw, 2009, 9(1): 20-26. 被引量:1
  • 9Riezebos BA, Regts J, Chen M, et al. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by coexpression of interleukin-12[J]. Vaccine, 2009, 27(5): 701-707. 被引量:1
  • 10Leitner WW, Ying H, Driver DA, et al. Enhancement of tumorspecific immune response with plasmid DNA replicon vectors[J]. Cancer Res, 2000, 60(1): 51-55. 被引量:1

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部